Tag: Eisai
Biogen reprioritizes Alzheimer’s disease resources, discontinues ADUHELM development
Biogen Inc. (Nasdaq: BIIB), a leading pharmaceutical company, today announced a strategic reprioritization of its resources in Alzheimer’s disease (AD), a key therapeutic area expected ... Read More
Eisai, Biogen secure Leqembi FDA accelerated approval for Alzheimer’s disease
Eisai and Biogen have secured the approval of the US Food and Drug Administration (FDA) for their jointly developed Leqembi (lecanemab-irmb) under the accelerated approval ... Read More
Dr. Reddy’s Labs signs deal worth up to $150m to sell E7777 rights to Citius
Dr. Reddy's Laboratories (Dr. Reddy's Labs) has agreed to divest its rights to E7777, an engineered IL-2-diphtheria toxin fusion protein, and certain related assets to ... Read More
Glenmark Pharmaceuticals launches Rufinamide Tablets in US
Glenmark Pharmaceuticals said that it has launched Rufinamide Tablets USP, 200 mg and 400 mg in the US, which is a therapeutic equivalent of Banzel ... Read More
Gilead, Galapagos bag Jyseleca EC approval for rheumatoid arthritis
Jyseleca EC approval : Gilead Sciences and Galapagos have secured marketing authorization for Jyseleca (filgotinib 200 mg and 100 mg tablets) from the European Commission ... Read More
Eisai, Merck bag Lenvima FDA approval for unresectable HCC
Lenvima FDA appoval : Eisai and Merck announced that the US Food and Drug Administration (FDA) has approved their kinase inhibitor Lenvima (lenvatinib) capsules for ... Read More